Detalles de la búsqueda
1.
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Cancer
; 126(18): 4156-4167, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32673417
2.
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
J Immunother Cancer
; 10(11)2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36328377
3.
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Eur Urol
; 81(3): 266-271, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34750035
4.
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Clin Cancer Res
; 27(1): 78-86, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32873572
5.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
ESMO Open
; 5(6): e001079, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33246931
6.
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial.
J Immunother Cancer
; 8(2)2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32661118
Resultados
1 -
6
de 6
1
Próxima >
>>